Moderna Stock Pops as FDA Application Moves Forward

Core Viewpoint - Moderna Inc is experiencing a positive market response following the acceptance of its flu vaccine application by the U.S. FDA, which had been modified after a previous rejection [1] Group 1: Stock Performance - Moderna's stock increased by 5.7%, trading at $46.45, marking a potential third consecutive gain [1] - The stock has risen 55.4% since the beginning of the year, approaching its January 22 high of $55.20 [1] Group 2: Market Dynamics - Short interest in Moderna stock is at 19.8% of the available float, indicating over six days of potential buying power [2] - The majority of brokerages (22 out of 24) have a "hold" or worse rating on the stock, suggesting potential for upgrades if the stock continues to rise [2] - The 12-month consensus price target for Moderna is $41.01, which is approximately an 11% discount to current trading levels [2]